Assessment of textbook outcome after lobectomy for early-stage non-small cell lung cancer in a Korean institution: A retrospective study

Woo Sik Yu | Jaeyong Shin | Jung A Son | Joonho Jung | Seokjin Haam

1Department of Thoracic and Cardiovascular Surgery, Ajou University School of Medicine, Suwon, Korea
2Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea

Correspondence
Seokjin Haam, Department of Thoracic and Cardiovascular Surgery, Ajou University School of Medicine, 164, World cup-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do 16499, Republic of Korea. Email: haamsj@aumc.ac.kr
Jaeyong Shin, Department of Preventive Medicine, College of Medicine, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea. Email: drshin@yuhs.ac

Abstract

Background: Textbook outcome (TO) has been introduced as a novel composite measure for lung cancer surgery. We investigated TO after lobectomy for early-stage non-small cell lung cancer (NSCLC) in a Korean tertiary hospital and its prognostic implications for overall survival and recurrence.

Methods: Between January 2012 and December 2017, 418 consecutive patients who underwent lobectomy for clinical stages I and II NSCLC were identified and retrospectively reviewed. TO was defined as complete resection (negative resection margins and sufficient lymph node dissection), no 30-day or in-hospital mortality, no reintervention within 30 days, no readmission to the intensive care unit, no prolonged hospital stay (<14 days), no hospital readmission within 30 days, and no major complications. Propensity score matching analysis was performed to investigate the association between TO, medical costs, and long-term outcomes.

Results: Of 418 patients, 277 (66.3%) achieved TO. The most common events leading to TO failure were prolonged air leakage (n = 54, 12.9%) and prolonged hospital stay (n = 53, 12.7%). Male sex (odds ratio [OR] = 2.148, p = 0.036) and low diffusing capacity for carbon monoxide (OR = 0.986, p = 0.047) were significant risk factors for failed TO in multivariate analysis. In matched cohorts, achieving TO was associated with lower medical costs and better overall survival but not cancer recurrence.

Conclusions: TO is associated with low medical cost and favorable overall survival; thus, surgical teams and hospitals should make efforts to improve the quality of care and achieve TO.

KEYWORDS
carcinoma, healthcare, non-small cell lung cancer, quality indicators, thoracic surgery

INTRODUCTION

Lung cancer is the leading cause of cancer-related death in Korea and worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancers, and surgery is the mainstay of treatment for early-stage NSCLC. The total number of lung cancer surgeries performed has increased over time in Korea. However, the number of extensive resections, such as bilobectomy or pneumonectomy, has decreased. This trend may be associated with the increased use of computed tomography (CT), which results in more lung cancer detected in earlier stages, indicating less extensive surgical treatment. Early detection and increased use of surgical treatment may be related to recent improvements in the prognosis of lung cancer in Korea, and this trend may continue in the future with the increased use of low-dose chest CT as a lung cancer screening program.

The quality of surgical care may have a great impact on the short- and long-term outcomes of lung cancer surgery. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Thoracic Cancer. 2022;13:1211–1219. wileyonlinelibrary.com/journal/tca | 1211
In addition, quality measurements can help patients choose hospitals and lead hospitals and their health care workers to improve their quality of surgical care. To define the quality of surgical care, various metrics have been proposed. However, quality should be a multi-dimensional construct that cannot be measured using a single metric. Textbook outcome (TO) has been introduced as a novel composite measure in various oncological surgical fields, such as colon, esophageogastric, and pancreatic cancer surgeries. TO defines such composite measurements by accounting for multiple postoperative endpoints that may reflect the ideal or “textbook” postoperative outcomes.

Recently, TO was defined and analyzed in lung cancer surgery using nationwide cohorts, including the Dutch Lung Cancer Audit-Surgery (DLAS-S) of the Netherlands and the National Cancer Database (NCBD) of the United States. TO was achieved in about 26% of cases in both series, and insufficient lymph node (LN) assessment was the most frequent cause of failure to achieve TO (DLAS-S, 55%; NCBD, 59.2%). Kulshrestha et al. also showed an association between the achievement of TO and improved overall survival (OS) in their analysis of the NCBD, but they could not assess cancer-specific outcomes because of the lack of data. Intercontinental variation in lung cancer surgery has been suggested, especially in LN examinations, but TO has never been analyzed in Asia. In the present study, we investigated TO after lobectomy for early-stage NSCLC in a Korean tertiary hospital and its prognostic implications for OS and recurrence.

METHODS

Patients

In reviewing electronic medical records, we identified patients with NSCLC who underwent surgical treatment between January 2012 and December 2017. Among them, we identified patients who underwent lobectomy for clinical stage I and II NSCLC. Patients who underwent sublobar resection, bilobectomy, or pneumonectomy were excluded because the ideal postoperative course (TO) may have differed according to the extent of lung resection. We also excluded patients who received neoadjuvant treatment, those with pleural seeding incidentally detected intraoperatively, and those with adenocarcinoma in situ or microinvasive adenocarcinoma because these may have influenced the operation and extent of LN dissection.

Data collection

Patient demographic and clinical characteristics included age, sex, smoking status, Charlson comorbidity index (CCI), pulmonary function test, tumor histology, harvested LN, clinical and pathological stage, operation approach, and medical cost. Staging was determined by the eighth edition of the tumor-node-metastasis (TNM) classification. Medical cost was calculated as the total cost during index hospitalization and readmission within 30 days. Follow-up for this study was completed in August 2021.

Definition of textbook outcome

We followed the definition for TO from the Dutch Lung Cancer Audit. TO was achieved when all the following desired outcomes were satisfied: negative resection margin and sufficient resection margin, no 30-day or in-hospital mortality, no reintervention (reoperation, bronchoscopy for atelectasis, and percutaneous drainage) within 30 days after the primary operation, no readmission to the intensive care unit (ICU) or prolonged ICU stay due to complications, no prolonged hospital stay (<14 days), no hospital readmission within 30 days, no major complications including prolonged air leakage (≥5 days), respiratory failure (acute respiratory distress syndrome and pulmonary edema), myocardial infarction, thromboembolic complications, chylothorax, empyema and/or bronchopleural fistula (BPF), and blood transfusion. Sufficient LN dissection followed the Union for International Cancer Control (UICC) recommendation. It was defined as the dissection or sampling of at least six LNs: three removed from intrapulmonary and/or hilar stations, and three removed from mediastinal stations, one of which must be the subcarinal station.

Statistical analyses

Continuous variables were compared using a Student’s t-test. Categorical variables were compared using the chi-square test or Fisher’s exact test. Risk factors for failed TO were analyzed.
using a binary logistic regression test. We constructed a multi-
variable model with clinically relevant variables (full model)
and another model with backward stepwise selection (step
wise model). Propensity score-matched analysis was per-
formed to overcome the differences in preoperative variables.
Propensity scores were calculated using a logistic regression
model that included the following variables: age, sex, smoking
status, CCI, pulmonary function test results (forced expiratory
volume in 1 second and diffusing capacity for carbon monox-
ide [DLCO]), histology, tumor size, and clinical stage. Propen-
sity scores were then matched to obtain pairs of matched
patients in a 1:1 manner, using nearest matching without
replacement. The balance of covariates between the failed TO
group (those who failed TO) and achieved TO group (those
who achieved TO) was assessed using standardized mean dif-
fferences, with adequacy considered to be <0.2.

OS was calculated using the Kaplan–Meier method and
compared using the log-rank test. The cumulative incidence of
recurrence with death as a competing risk factor was compared
using the Fine and Gray method. Statistical significance was set
at p ≤ 0.05. Statistical analyses were performed using R version
4.1.0 (R Foundation for Statistical Computing).

| Variable                  | All patients (N = 418) | Achieved TO (N = 277) | Failed TO (N = 141) | p-value |
|---------------------------|------------------------|-----------------------|---------------------|---------|
| Age, years, mean ± SD     | 63.6 ± 10.0            | 63.0 ± 9.9            | 64.9 ± 10.1         | 0.060   |
| Sex                       |                        |                       |                     | <0.001  |
| Male                      | 273 (65.3%)            | 163 (58.8%)           | 110 (78.0%)         |         |
| Female                    | 145 (34.7%)            | 114 (41.2%)           | 31 (22.0%)          |         |
| Smoking                   |                        |                       |                     | <0.001  |
| Non-smoker                | 163 (39.0%)            | 126 (45.5%)           | 37 (26.2%)          |         |
| Ex-smoker                 | 128 (30.6%)            | 82 (29.6%)            | 46 (32.6%)          |         |
| Current smoker            | 127 (30.4%)            | 69 (24.9%)            | 58 (41.1%)          |         |
| CCI                       |                        |                       |                     | 0.018   |
| 0                         | 197 (47.1%)            | 143 (51.6%)           | 54 (38.3%)          |         |
| 1                         | 94 (22.5%)             | 61 (22.0%)            | 33 (23.4%)          |         |
| >2                        | 127 (30.4%)            | 73 (26.4%)            | 54 (38.3%)          |         |
| FEV1, % predicted         | 93.0 ± 13.8            | 93.5 ± 12.9           | 91.9 ± 15.3         | 0.271   |
| DLCO, % predicted         | 77.0 ± 20.0            | 80.0 ± 19.3           | 71.0 ± 20.1         | <0.001  |
| Approach                  |                        |                       |                     | 0.009   |
| VATS                      | 277 (66.3%)            | 196 (70.8%)           | 81 (57.4%)          |         |
| Thoracotony               | 141 (33.7%)            | 81 (29.2%)            | 60 (42.6%)          |         |
| Histology                 |                        |                       |                     | <0.001  |
| Adeno                     | 286 (68.4%)            | 208 (75.1%)           | 78 (55.3%)          |         |
| Sq                        | 97 (23.2%)             | 47 (17.0%)            | 50 (35.5%)          |         |
| Other NSCLC               | 35 (8.4%)              | 22 (7.9%)             | 13 (9.2%)           |         |
| Tumor size, cm            | 3.1 ± 1.7              | 2.9 ± 1.5             | 3.4 ± 2.0           | 0.014   |
| Harvested LNs, n          | 24.0 ± 11.5            | 25.0 ± 11.0           | 22.0 ± 12.1         | 0.010   |
| Clinical stage            |                        |                       |                     | 0.221   |
| IA                        | 151 (34.1%)            | 96 (34.7%)            | 55 (39.0%)          |         |
| IB                        | 193 (43.2%)            | 137 (49.5%)           | 56 (39.7%)          |         |
| IIA                       | 10 (2.4%)              | 5 (1.8%)              | 5 (3.5%)            |         |
| IIB                       | 64 (15.3%)             | 39 (14.1%)            | 25 (17.7%)          |         |
| Pathological stage        |                        |                       |                     | 0.271   |
| IA                        | 129 (30.9%)            | 88 (31.8%)            | 41 (29.1%)          |         |
| IB                        | 145 (34.7%)            | 104 (37.5%)           | 41 (29.1%)          |         |
| IIA                       | 25 (6.0%)              | 14 (5.1%)             | 11 (7.8%)           |         |
| IIB                       | 59 (14.1%)             | 33 (11.9%)            | 26 (18.4%)          |         |
| IIIA                      | 52 (12.4%)             | 33 (11.9%)            | 19 (13.5%)          |         |
| IIIB                      | 8 (1.9%)               | 5 (1.8%)              | 3 (2.1%)            |         |

Abbreviations: Adeno, adenocarcinoma; CCI, Charlson comorbidity index; DLCO, diffusing capacity for carbon monoxide; FEV1, forced expiratory volume in 1 s; LN, lymph node; SD, standard deviation; TO, textbook outcome; VATS, video-assisted thoracoscopic surgery; NSCLC, non-small cell lung cancer; Sq, squamous cell carcinoma.
RESULTS

Baseline characteristics

A total of 418 patients were enrolled in this study (Figure 1). The demographic and medical characteristics are presented in Table 1. Of 418 patients, 277 (66.3%) achieved TO. Compared to the failed TO group, the achieved TO group showed a lower proportion of men, less smoking history, lower CCI, and higher DLCO. The achieved TO group was more likely to have adenocarcinomas and smaller tumors than the failed TO group. More LNs were harvested during surgery in the achieved TO group than in the failed TO group.

Prevalence of events leading to textbook outcome failure

The most common events leading to TO failure were prolonged air leakage (n = 54, 12.9%) and prolonged hospital stay (n = 53, 12.7%). The patients with prolonged air leakage had significantly longer hospital stays compared with patients without prolonged air leakage (17.1 ± 11.4 vs. 8.4 ± 8.2, p < 0.001, respectively) and 30 patients (55.6%) with prolonged air leakage also had
### Table 3: Predicted factors for achievement of textbook outcome according to the logistic regression model

| Variable                        | Full model | Stepwise model |
|---------------------------------|------------|----------------|
|                                 | OR         | 95% CI         | p-value | OR         | 95% CI         | p-value |
| Age                             | 0.997      | 0.970–1.025    | 0.836   | 2.162      | 1.350–3.526    | 0.002   |
| Male (vs. female)               | 2.148      | 1.050–4.405    | 0.036   | 2.162      | 1.350–3.526    | 0.002   |
| Smoking                         |            |                |         |            |                |         |
| Non-smoker                      | Reference  |                |         |            |                |         |
| Ex-smoker                       | 0.711      | 0.325–1.559    | 0.391   |            |                |         |
| Current smoker                  | 1.178      | 0.551–2.523    | 0.672   |            |                |         |
| CCI ≥ 2                         | 1.582      | 0.985–2.538    | 0.057   | 1.501      | 0.949–2.365    | 0.081   |
| Preop FEV1, % predicted         | 0.999      | 0.982–1.016    | 0.882   |            |                |         |
| Preop DLCO, % predicted         | 0.986      | 0.972–1.000    | 0.047   | 0.982      | 0.971–0.993    | 0.002   |
| VATS (vs. open)                 | 0.727      | 0.451–1.178    | 0.193   | 0.650      | 0.416–1.017    | 0.058   |
| Histology                       |            |                |         |            |                |         |
| Adeno                           | Reference  |                |         |            |                |         |
| Sq                              | 1.618      | 0.919–2.846    | 0.095   |            |                |         |
| Other NSCLC                     | 1.141      | 0.511–2.455    | 0.741   |            |                |         |
| Tumor size, cm                  | 1.121      | 0.963–1.311    | 0.144   |            |                |         |
| Clinical stage                  |            |                |         |            |                |         |
| I                               | Reference  |                |         |            |                |         |
| II                              | 0.699      | 0.363–1.313    | 0.273   |            |                |         |

Abbreviations: Adeno, adenocarcinoma; CCI, Charlson comorbidity index; CI, confidence interval; DLCO, diffusing capacity for carbon monoxide; FEV1, forced expiratory volume in 1 s; NSCL, non-small cell lung cancer; OR, odds ratio; Sq, squamous cell carcinoma; VATS, video-assisted thoracoscopic surgery.

### Table 4: Baseline characteristics of the achieved and failed textbook outcome groups in the matched cohort

| Achieved TO (n = 128) | Failed TO (n = 128) | SMD |
|-----------------------|---------------------|-----|
| Age, years, mean ± SD | 63.5 ± 9.6          | 64.4 ± 10.3 | 0.096 |
| Male sex              | 100 (78.1)          | 99 (77.3)   | 0.019 |
| Smoking               | 0.055               |            |     |
| Non-smoker            | 36 (28.1)           | 36 (28.1)   |     |
| Ex-smoker             | 41 (32.0)           | 44 (34.4)   |     |
| Current smoker        | 51 (39.8)           | 48 (37.5)   |     |
| CCI                   | 0.073               |            |     |
| 0                     | 50 (39.1)           | 52 (40.6)   |     |
| 1                     | 33 (25.8)           | 29 (22.7)   |     |
| ≥2                    | 45 (35.2)           | 47 (36.7)   |     |
| Preop FEV1, % predicted| 95.52 (13.03)       | 92.26 (14.67)| 0.019 |
| Preop DLCO, % predicted| 74.93 (18.20)       | 72.90 (19.46)| 0.108 |
| VATS                  | 79 (61.7)           | 77 (60.2)   | 0.032 |
| Histology             | 0.027               |            |     |
| Adeno                 | 75 (58.6)           | 76 (59.4)   |     |
| Sq                    | 40 (31.2)           | 40 (31.2)   |     |
| Other NSCLC           | 13 (10.2)           | 12 (9.4)    |     |
| Tumor size, cm        | 3.2 ± 1.5           | 3.2 ± 1.7   | 0.013 |
| Clinical stage        | 0.163               |            |     |
| IA                    | 47 (36.7)           | 50 (39.1)   |     |
| IB                    | 57 (44.5)           | 54 (42.2)   |     |
| IIA                   | 5 (3.9)             | 2 (1.6)     |     |
| IIB                   | 19 (14.8)           | 22 (17.2)   |     |

(Continues)
a prolonged hospital stay. Of 54 patients with prolonged air leakage, 39 (72.2%) patients received bedside pleurodesis, and two (3.7%) underwent reoperation with general anesthesia. The least common events were myocardial infarction \((n = 2, 0.5\%\) and empyema/BPF \((n = 3, 0.7\%)\) (Figure 2 and Table 2). Among patients with failed TO, 84 (59.6%) had a single complication (Figure 3).

**Risk factors for textbook outcome failure**

Risk factors for failed TO according to binary logistic regression analysis are shown in Table 3. In the full model with possible relevant variables and stepwise model with backward selection, male sex and low DLCO were significant risk factors for failed TOs.

---

**Propensity-matched analysis**

To investigate the impact of TO achievement on long-term outcomes, we performed propensity-matched analysis, which resulted in 128 well-balanced pairs of patients (Table 4).

In both unmatched and matched cohorts, medical costs were 1.5 times higher for failed TO than for achieved TO (unmatched cohorts, $15936.7 \pm 13882.8$ vs. $10912.1 \pm 3574.1$, respectively; \(p < 0.001\); matched cohort, $15471.8 \pm 13610.7$ vs. $10813.6 \pm 2208.8$, respectively, \(p < 0.001\); Figure 4).

In unmatched cohorts, the achieved TO group had better 3- and 5-year OS rates than the failed TO group (95.0% and 90.7% vs. 87.4% and 80.3%, respectively; \(p = 0.018\)). There was no significant difference in the cumulative incidence of recurrence at 3- and 5-years between the achieved TO and failed TO groups (7.2% and 18.6% vs. 9.1% and

---

**TABLE 4**

(Continued)

| Pathological stage | Achieved TO \((n = 128)\) | Failed TO \((n = 128)\) | SMD |
|-------------------|---------------------------|-------------------------|-----|
| IA                | 40 (31.2)                 | 38 (29.7)               | 0.144 |
| IB                | 41 (32.0)                 | 40 (31.2)               |     |
| IIA               | 11 (8.6)                  | 10 (7.8)                |     |
| IIB               | 16 (12.5)                 | 21 (16.4)               |     |
| IIIA              | 15 (11.7)                 | 16 (12.5)               |     |
| IIIB              | 5 (3.9)                   | 3 (2.3)                 |     |

Abbreviations: Adeno, adenocarcinoma; CCI, Charlson comorbidity index; DLCO, diffusing capacity for carbon monoxide; FEV1, forced expiratory volume in 1 s; NSCL, non-small cell lung cancer; SD, standard deviation; SMD, standardized mean difference; VATS, video-assisted thoracoscopic surgery; Sq, squamous cell carcinoma.
In matched cohorts, the achieved TO group still had better 3- and 5-year OS rates than the failed TO group (95.0% and 89.3% vs. 92.0% and 81.7%, respectively; \( p = 0.027 \)). There was no significant difference in the cumulative incidence of recurrence at 3- and 5-years between the achieved TO and failed TO groups (7.5% and 9.0% vs. 21.5% and 24.4%, respectively; \( p = 0.481 \)) (Figure 5).

**DISCUSSION**

To the best of our knowledge, this is the first study to analyze TO in lung cancer patients in Asia. Of 418 patients enrolled into the study who underwent lobectomy for clinical stage I and II NSCLC, 66.3% of patients achieved TO. Prolonged air leakage and hospital stay were the most frequent causes of TO failure. Male sex and a low DLCO were significant risk factors for failed TO. TO was associated with lower medical costs and favorable OS but not recurrence in the propensity-matched analysis.

Defining, measuring, and delivering high-quality surgical care in patients with lung cancer is complex. Various metrics have been suggested, and none of the single metrics can fully reflect all the multistep processes in lung cancer surgical care. Postoperative morbidity and mortality are considered important quality metrics. However, the individual event rate and variation of these events are low, which makes them less suitable for detecting hospital variations and measuring quality improvement.

TO represents ideal postoperative outcomes with various components and results in binary outcomes (achieved or failed TO). This is more understandable and informative for patients than a single metric is. Furthermore, variations in TO between hospitals and surgeons may be larger than a single metric and may provide information about their specific improvement potentials. In the present study, 33.7% of patients had a failed TO. Prolonged air leakage and hospital stay were the most frequent causes of failure in 12.9% and 12.7% of cases, respectively and 55.6% of patients with prolonged air leakage also had prolonged hospital stay, whereas the failure rates of other criteria were < 10%. Additionally, 59.6% of the patients with failed TO failed only one of the criteria. This suggests that we have the potential to improve our TO, and efforts need to be made to reduce cases of air leakage at our institution.
The DLAS-S used the definition of dissection or sampling of a minimum of three mediastinal LNs (including at least one in the subcarinal station) and hilar and intrapulmonary LNs according to the European Society of Thoracic Surgeons guidelines. Kulshrestha et al. used a threshold of 10 LNs for sufficient LN assessment to be consistent with the Commission on Cancer quality metric in the analysis of NCBD data. In these studies, the insufficient LN assessment was the most frequent cause of failure to achieve TO. In the present study, we used the Union for International Cancer Control recommendation for criteria of sufficient LN dissection, which was defined as at least three LNs removed from the N1 stations and three LNs removed from the N2 stations. Despite the stricter definition for sufficient LN dissection, the failure of sufficient LN dissection was only 8.1%.

The International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee demonstrated significant differences in the survival of patients with pN0, pN1, and pN2 NSCLCs in the international database. Asian patients (mostly from South Korea and Japan) with pN0 disease had a 5-year survival rate of 79% compared with 5-year survival rates of 67% for Americans, 58% for Australians, and 54% for Europeans. The disparities in survival of patients with pN2 were much lower (39, 42, 33, and 22%, respectively). One of the hypotheses for these survival differences is the intercontinental variation in lung cancer surgery, especially in the thoroughness of the LN examination. In the present study, the mean number of resected LNs was 24.0 ± 11.5, which is consistent with that in previous reports from other Korean tertiary centers. Approximately 80% of lung cancer surgeries are performed in tertiary centers in Korea, so the failure rate of sufficient LN dissection in Korea might also be quite low compared with that in previous reports from the DLAS-S and NCBD. However, to confirm this postulation, a nationwide database including details of LN evaluations needs to be established in Korea.

In the current study, male sex and low DLCO were risk factors for failed TO. Additionally, in previous reports, age, comorbidities, lung function, socioeconomic status, facility type, tumor size, and surgical approach were associated with TO. Most of those variables are not modifiable and are associated with operative risks. Therefore, care should be taken before using TO to compare hospitals and surgeons, and case-mix should be considered. In fact, our cohort was younger and had fewer comorbidities than those in previous reports, and we only included patients with early-stage lung cancer and lobectomy, which might be one of the reasons for the higher TO in our study than in previous reports.

Because most of the individual criteria for TO are already known to be related to survival, such as complete resection, postoperative pulmonary complication, and readmission within 30 days, it is not surprising that the achievement of TO is associated with favorable OS. Previous reports of NCBD have shown an association of TO with improved survival, but have not shown disease-specific outcomes, such as recurrence. In the present study, we investigated the effect of TO on both survival and recurrence. To minimize confounding factors, we used propensity-matched analysis. We found a significant difference in OS in the unmatched and matched cohorts. However, we failed to find any difference in recurrence between the cohorts in the competing risk model. This finding suggests that the survival benefit from achieving TO would be associated with decreased noncancer-related deaths in our cohort.

This study has several limitations. This was a single-center retrospective study which included a small number of patients. The rate of TO achievement and cause of failure were quite different from those in previous reports from Western countries. We did not find a significant difference in recurrence according to the TO achievement. This might be a type 2 error due to the small number of patients and the high rate of sufficient LN dissection. A nationwide prospective study including a large number of patients is necessary to confirm the presence of internal variation in lung cancer surgery and the association between TO and recurrence.

In conclusion, TOs can be useful in assessing surgical quality, and the assessment of TO provides hospitals and surgeons the opportunity to review their practice for ideal postoperative outcomes. TO is associated with lower medical costs and favorable OS; thus, caregivers participating in lung cancer surgery and perioperative care should make an effort to improve the quality of care and achieve TO. Further nationwide studies are necessary to understand the quality variation and national characteristics of lung cancer surgery.

ACKNOWLEDGMENTS
None.

CONFLICT OF INTEREST
The authors declare that they have no actual or potential conflicts of interest regarding the work reported herein.

ORCID
Woo Sik Yu https://orcid.org/0000-0002-0403-2216

REFERENCES
1. Hong S, Won Y-J, Lee JJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2018. Cancer Res Treat. 2021; 53(2):301–15.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
3. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367–80.
4. Kim D, Kang GW, Jang H, et al. Trend of lung cancer surgery, hospital selection, and survival between 2005 and 2016 in South Korea. Thoracic Cancer. 2021;13:210–218. https://doi.org/10.1111/1759-7714.14247
5. Park S, Park IK, Kim ER, et al. Current trends of lung cancer surgery and demographic and social factors related to changes in the trends of lung cancer surgery: an analysis of the National Database from 2010 to 2014. Cancer Res Treat. 2017;49(2):330–7.
6. Shin A, Oh C-M, Kim B-W, Woo H, Won Y-J, Lee J-S. Lung cancer epidemiology in Korea. Cancer Res Treat. 2017;49(3):616–26.
7. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409.

8. Smeltzer MP, Faris NR, Ray MA, et al. Survival before and after direct surgical quality feedback in a population-based lung cancer cohort. Ann Thorac Surg. 2019;107(5):1487–93.

9. Brandt WS, Isbell JM, Jones DR. Defining quality in the surgical care of lung cancer patients. J Thorac Cardiovasc Surg. 2017;154(4):1397–403.

10. Farjah F, Detterbeck FC. What is quality, and can we define it in lung cancer? The case for quality improvement. Transl Lung Cancer Res. 2015;4(4):365–72.

11. van Roessel S, Mackay TM, van Dieren S, et al. Textbook outcome: nationwide analysis of a novel quality measure in pancreatic surgery. Ann Surg. 2020;271(1):155–62.

12. Busweiler LAD, Schouwenburg MG, Van Berge Henegouwen MI, et al. Textbook outcome as a composite measure in oesophago gastric cancer surgery. Br J Surg. 2017;104(6):742–50.

13. Kolfschoten NE, Kievit J, Gooiker GA, et al. Focusing on desired outcomes of care after colon cancer resections; hospital variations in ‘textbook outcome’. Eur J Surg Oncol. 2013;39(2):156–63.

14. Halpern SE, Moris D, Gloria JN, et al. Textbook outcome: definition and analysis of a novel quality measure in lung transplantation. Ann Surg. 2021. https://doi.org/10.1097/sla.0000000000004916

15. Kulshrestha S, Vigneswaran WT, Pawlik TM, et al. Assessment of textbook outcome after surgery for stage I/II non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 2021. https://doi.org/10.1053/j.semtcv.2021.08.009

16. Ten Berge MG, Beck N, Steup WH, et al. Textbook outcome as a composite outcome measure in non-small-cell lung cancer surgery. Eur J Cardiothorac Surg. 2021;59(1):92–9.

17. Smeltzer MP, Faris NR, Ray MA, Osarogiagbon RU. Association of pathologic nodal staging quality with survival among patients with non–small cell lung cancer after resection with curative intent. JAMA Oncol. 2018;4(1):80.

18. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.

19. Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51.

20. Rami-Porta R, Wittekind C, Goldstraw P. Complete resection in lung cancer surgery: proposed definition. Lung Cancer. 2005;49(1):25–33.

21. Lardinois D, Deleyn P, Vanschil P, et al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardiothorac Surg. 2006;30(5):787–92.

22. Asamura H, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;10(12):1675–84.

23. Osarogiagbon RU, Smeltzer MP, Faris N, Rami-Porta R, Goldstraw P, Asamura H. Comment on the proposals for the revision of the N descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(10):1612–4.

24. Yun JK, Lee GD, Choi S, et al. Comparison between lymph node station- and zone-based classification for the future revision of node descriptors proposed by the International Association for the Study of Lung Cancer in surgically resected patients with non-small-cell lung cancer. Eur J Cardiothorac Surg. 2019;56(5):849–57.

25. Suh JW, Park SY, Lee CY, et al. Feasibility and surgical outcomes of video-assisted thoracoscopic pulmonary resection in patients with advanced-stage lung cancer after neoadjuvant chemoradiotherapy. Thorac Cancer. 2019;10(5):1241–7.

26. Shin S, Kang D, Cho JH, et al. Prognostic impact of lymph node ratio in patients with pT1-2N1M0 non-small cell lung cancer. J Thorac Dis. 2020;12(10):5552–60.

27. Lee SY, Jeon JH, Jung W, et al. Predictive factors for lymph node metastasis in clinical stage I part-solid lung adenocarcinoma. Ann Thorac Surg. 2021;111(2):456–62.

28. Lugg ST, Agostini PJ, Tikka T, et al. Long-term impact of developing a postoperative pulmonary complication after lung surgery. Thorax. 2016;71(2):171–6.

29. Puri V, Patel AP, Crabtree TD, et al. Unexpected readmission after lung cancer surgery: a benign event? J Thorac Cardiovasc Surg. 2015;150(6):1496–504. 505.e1-5; discussion 504-5.